Evidence map›Paper›PMID 40729189›Full record

ArticleReports (MDPI)2023

The Effects of a Combination of Medical Cannabis, Melatonin, and Oxygen-Ozone Therapy on Glioblastoma Multiforme: A Case Report.

Marina Antonini, Cristina Aguzzi, Alessandro Fanelli, Andrea Frassineti, Laura Zeppa, Maria Beatrice Morelli, Gabriella Pastore, Massimo Nabissi, Margherita Luongo

Abstract readCase Reports
In one paragraph

Article in Reports (MDPI), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marina AntoniniFondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Roma, Italy.
Cristina AguzziSchool of Pharmacy, University of Camerino, 62032 Camerino, Italy.ORCID 0000-0002-8508-6389
Alessandro FanelliClinical Research Institute Ecomedica, 50053 Empoli, Italy.
Andrea Frassineti"Maria Guarino" Foundation-Amor No Profit Association, 80078 Pozzuoli, Italy.
Laura ZeppaSchool of Pharmacy, University of Camerino, 62032 Camerino, Italy.ORCID 0000-0001-6196-9673
Maria Beatrice MorelliSchool of Pharmacy, University of Camerino, 62032 Camerino, Italy.ORCID 0000-0002-4614-5649
Gabriella PastoreClinical Research Institute Ecomedica, 50053 Empoli, Italy.
Massimo NabissiSchool of Pharmacy, University of Camerino, 62032 Camerino, Italy.ORCID 0000-0003-0165-1385
Margherita Luongo"Maria Guarino" Foundation-Amor No Profit Association, 80078 Pozzuoli, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma is the most aggressive malignant tumor overall and remains an incurable neoplasm with a median survival of 15 months. Since 2005, the gold standard treatment for glioblastoma has remained unchanged, and it is a common goal of the scientific community to work towards a better prognosis and improved survival for glioblastoma patients. Herein, we report a case of glioblastoma multiforme in a patient with a poor prognosis who, following partial removal of the neoplasm, refused conventional therapy consisting of a combination of radiotherapy and temozolomide-based chemotherapy due to personal serious side effects. The patient started an unconventional therapeutic path by alternating periods of oxygen-ozone therapy with concomitant administration of legal medical cannabis products (Bedrocan and Bedrolite) and melatonin. This approach resulted in a complete and durable remission of the disease and long survival. Indeed, the patient is still alive. The exceptional result obtained here encourages us to share and carefully investigate this unconventional treatment as a possible future direction in the management of glioblastoma.

Indexed as

cannabinoidschemotherapyglioblastomamelatoninoxygen–ozone therapyradiotherapy

Identifiers

PMID40729189
PMCPMC12225241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.